Depot Naltrexone Treatment of Opioid Dependent Parolees

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00756990
Recruitment Status : Completed
First Posted : September 22, 2008
Last Update Posted : October 2, 2015
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
This is an investigation involving the use of a long-acting, injectable form (depot) of naltrexone as a treatment for persons who have a history of opioid dependence, with up to 40 on parole/probation and 20 non-parolees. The test is a pilot study of up to 60 subjects treated with 6 months of depot naltrexone plus Psychosocial Treatment .

Condition or disease Intervention/treatment Phase
Opioid Dependence Drug: Depot Naltrexone Not Applicable

Detailed Description:
This is a two phase study. Phase 1 is complete and phase 2 is not yet recruiting.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Depot Naltrexone Treatment of Opioid Dependent Parolees
Study Start Date : November 2005
Actual Primary Completion Date : March 2009
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single group
Depot Naltrexone
Drug: Depot Naltrexone
228mg of injectable naltrexone
Other Name: Depotrex

Primary Outcome Measures :
  1. UDS results [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Treatment completion [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion/Exclusion Criteria.

To be eligible to participate, participants must:

  • sign an informed consent form;
  • be between the ages of 18 and 55;
  • have a diagnosis of opioid dependence according to DSM IVTR criteria; and
  • be in good general health as determined by complete physical examination and laboratory tests;
  • have been assigned to a probation/parole period of at least six months; (except those participants not on parole/probation, see note below); and
  • have a negative result for urinary opioids and must self report being at least 3 days opioid free. Participants may have a diagnosis of alcohol dependence so long as they do not have severe alcohol dependence that requires medical supervision for alcohol withdrawal.

Participants with the following characteristics will be excluded from study participation:

  • current severe alcohol dependence that requires medical supervision for alcohol withdrawal;
  • current psychosis, dementia, mental retardation, or history of schizophrenia;
  • significant clinical abnormalities in hematology, chemistry, or urinalysis;
  • significant clinical cardiovascular, neurological, hepatic, renal, pulmonary, metabolic, endocrine, or gastrointestinal disorders;
  • female subjects who are pregnant or lactating, or female subjects of childbearing potential who are not using birth control (oral contraceptives, barrier (diaphragm or condom) plus spermicide, or levonorgestriel implant);
  • subjects who have taken an opioid antagonist within the prior 6 months; and
  • current diagnosis of chronic pain disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00756990

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Principal Investigator: Charles O'Brien, MD,PhD University of Pennsylvania

Responsible Party: University of Pennsylvania Identifier: NCT00756990     History of Changes
Other Study ID Numbers: 708310
R01DA024553 ( U.S. NIH Grant/Contract )
First Posted: September 22, 2008    Key Record Dates
Last Update Posted: October 2, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents